Literature DB >> 17238006

5-Oxoproline reduces non-enzymatic antioxidant defenses in vitro in rat brain.

Carolina D Pederzolli1, Angela M Sgaravatti, César A Braum, Cristina C Prestes, Giovanni K Zorzi, Mirian B Sgarbi, Angela T S Wyse, Clóvis M D Wannmacher, Moacir Wajner, Carlos S Dutra-Filho.   

Abstract

5-Oxoproline (pyroglutamic acid) accumulates in glutathione synthetase deficiency, an inborn metabolic defect of the gamma-glutamyl cycle. This disorder is clinically characterized by hemolytic anemia, metabolic acidosis and severe neurological disorders. Considering that the mechanisms of brain damage in this disease are poorly known, in the present study we investigated whether oxidative stress is elicited by 5-oxoproline. The in vitro effect of (0.5-3.0 mM) 5-oxoproline was studied on various parameters of oxidative stress, such as total radical-trapping antioxidant potential, total antioxidant reactivity, chemiluminescence, thiobarbituric acid-reactive substances, sulfhydryl content, carbonyl content, and 2',7'-dichlorofluorescein fluorescence, as well as on the activities of the antioxidant enzymes catalase, superoxide dismutase and glutathione peroxidase in cerebral cortex and cerebellum of 14-day-old rats. Total radical-trapping antioxidant potential and total antioxidant reactivity were significantly reduced in both cerebral structures. Carbonyl content and 2',7'-dichlorofluorescein fluorescence were significantly enhanced, while sulfhydryl content was significantly diminished. In contrast, chemiluminescence and thiobarbituric acid-reactive substances were not affected by 5-oxoproline. The activities of catalase, superoxide dismutase and glutathione peroxidase were also not altered by 5-oxoproline. These results indicate that 5-oxoproline causes protein oxidation and reactive species production and decrease the non-enzymatic antioxidant defenses in rat brain, but does not cause lipid peroxidation. Taken together, it may be presumed that 5-oxoproline elicits oxidative stress that may represent a pathophysiological mechanism in the disorder in which this metabolite accumulates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17238006     DOI: 10.1007/s11011-006-9041-2

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  40 in total

Review 1.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?

Authors:  Barry Halliwell; Matthew Whiteman
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

2.  Studies on the malabsorption syndromes. Inhibition of (Na+-K+) ATPase of small intestine microvilli by pyrrolidone carboxylic acid.

Authors:  M Escobedo; J Cravioto
Journal:  Clin Chim Acta       Date:  1973-12-12       Impact factor: 3.786

3.  Pyroglutamic aciduria: rate of formation and degradation of pyroglutamate.

Authors:  L Eldjarn; E Jellum; O Stokke
Journal:  Clin Chim Acta       Date:  1973-12-27       Impact factor: 3.786

Review 4.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Oxidative damage to proteins: spectrophotometric method for carbonyl assay.

Authors:  A Z Reznick; L Packer
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

6.  Glutathione peroxidase.

Authors:  A Wendel
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Characterization of 2',7'-dichlorofluorescin fluorescence in dissociated mammalian brain neurons: estimation on intracellular content of hydrogen peroxide.

Authors:  Y Oyama; A Hayashi; T Ueha; K Maekawa
Journal:  Brain Res       Date:  1994-01-28       Impact factor: 3.252

8.  Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity.

Authors:  J D Rothstein; L Jin; M Dykes-Hoberg; R W Kuncl
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

Review 9.  Physiology and pathophysiology of organic acids in cerebrospinal fluid.

Authors:  G F Hoffmann; W Meier-Augenstein; S Stöckler; R Surtees; D Rating; W L Nyhan
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

10.  Effects of pyroglutamic acid on corticostriatal glutamatergic transmission.

Authors:  N Dusticier; L Kerkerian; M Errami; A Nieoullon
Journal:  Neuropharmacology       Date:  1985-09       Impact factor: 5.250

View more
  11 in total

1.  Acute administration of 5-oxoproline induces oxidative damage to lipids and proteins and impairs antioxidant defenses in cerebral cortex and cerebellum of young rats.

Authors:  Carolina Didonet Pederzolli; Caroline Paula Mescka; Bernardo Remuzzi Zandoná; Daniella de Moura Coelho; Angela Malysz Sgaravatti; Mirian Bonaldi Sgarbi; Angela Terezinha de Souza Wyse; Clóvis Milton Duval Wannmacher; Moacir Wajner; Carmen Regla Vargas; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2010-04-30       Impact factor: 3.584

2.  Discovery of a widespread prokaryotic 5-oxoprolinase that was hiding in plain sight.

Authors:  Thomas D Niehaus; Mona Elbadawi-Sidhu; Valérie de Crécy-Lagard; Oliver Fiehn; Andrew D Hanson
Journal:  J Biol Chem       Date:  2017-08-22       Impact factor: 5.157

3.  Metabolome-based signature of disease pathology in MS.

Authors:  S L Andersen; F B S Briggs; J H Winnike; Y Natanzon; S Maichle; K J Knagge; L K Newby; S G Gregory
Journal:  Mult Scler Relat Disord       Date:  2019-03-09       Impact factor: 4.339

4.  Therapeutic Effect of Buyang Huanwu Decoction on the Gut Microbiota and Hippocampal Metabolism in a Rat Model of Cerebral Ischemia.

Authors:  Rongmei Tang; Jian Yi; Shuangying Lu; Bowei Chen; Baiyan Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-14       Impact factor: 6.073

5.  Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study.

Authors:  Hitoshi Kuwabara; Hidenori Yamasue; Shinsuke Koike; Hideyuki Inoue; Yuki Kawakubo; Miho Kuroda; Yosuke Takano; Norichika Iwashiro; Tatsunobu Natsubori; Yuta Aoki; Yukiko Kano; Kiyoto Kasai
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

6.  Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart.

Authors:  A van der Pol; M F Hoes; R A de Boer; P van der Meer
Journal:  J Intern Med       Date:  2020-06-17       Impact factor: 8.989

7.  A multi-omic investigation of male lower urinary tract symptoms: Potential role for JC virus.

Authors:  Samuel Thomas; Christopher D Dunn; Lewis J Campbell; Douglas W Strand; Chad M Vezina; Dale E Bjorling; Kristina L Penniston; Lingjun Li; William A Ricke; Tony L Goldberg
Journal:  PLoS One       Date:  2021-02-25       Impact factor: 3.240

8.  Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease.

Authors:  Kaitlin Day; Lucia A Seale; Ross M Graham; Barbara R Cardoso
Journal:  Front Nutr       Date:  2021-11-17

9.  Multi Platforms Strategies and Metabolomics Approaches for the Investigation of Comprehensive Metabolite Profile in Dogs with Babesia canis Infection.

Authors:  Ivana Rubić; Richard Burchmore; Stefan Weidt; Clement Regnault; Josipa Kuleš; Renata Barić Rafaj; Tomislav Mašek; Anita Horvatić; Martina Crnogaj; Peter David Eckersall; Predrag Novak; Vladimir Mrljak
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 10.  Treating oxidative stress in heart failure: past, present and future.

Authors:  Atze van der Pol; Wiek H van Gilst; Adriaan A Voors; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2018-10-19       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.